– USA, CA – Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the appointment of Katie Peng to its Board of Directors.
“We are delighted to welcome Katie to our Board of Directors. Her proven success as a commercial leader in both the U.S. and globally will be particularly valuable to Adicet as we advance ADI-001 and our pipeline of allogeneic gamma delta T cell therapy candidates in hematologic and solid tumors,” said CEO, Chen Schor.
About Katie Peng
Katie Peng brings extensive industry and commercial expertise to the Board. She currently serves as CCO at Denali Therapeutics Inc., leading the global commercialization efforts of Denali’s pipeline. Previously Ms. Peng served as SVP of Head of the OMNI Business Unit at Genentech, Inc., where she was responsible for the oncology, neurology, and rare diseases portfolio representing approximately $14 billion in revenue, and served as part of Genentech’s commercial leadership team. Before Genentech, Ms. Peng held several senior leadership positions at Roche Holding AG, managing the Roche portfolio of over 30 products in the Asia Pacific region as the General Manager of two countries. Ms. Peng has successfully launched multiple products in neurology, oncology, and rare disease, notably including OCREVUS (ocrelizumab), a therapeutic monoclonal antibody approved for the treatment of multiple sclerosis, Evrysdi® (risdiplam), a medicine used to treat spinal muscular atrophy in adults and children, and HEMLIBRA (emicizumab-kxwh), a bispecific antibody for the treatment of people with hemophilia A. Her experience spans marketing, sales, market access, medical affairs, and business planning. Before joining Roche, Ms. Peng held several commercial roles at Amgen Inc. and began her career as a research scientist at Allergan plc.
“I am pleased to join the Adicet Board at this exciting time for the company,” said Ms. Peng. “As the company advances towards its potentially pivotal study of ADI-001 in post-CAR T large B-cell lymphoma, I look forward to working with my fellow board members and company management to prepare Adicet for the potential commercialization of ADI-001 and other future therapies.”
Mais Peng holds a B.A. from the University of California, Berkeley, and an M.B.A. from the Kelley School of Business, Indiana University. She also serves as a board member for California Life Sciences.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and chimeric antigen adaptors, to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients.
Source: https://www.adicetbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
